• July 13, 2022  

    Chronic Myelomonocytic Leukemia: 2022 Update on Diagnosis, Risk Stratification, and Management Bookmark

    George Lundberg, MD

    Written for oncology healthcare professionals, this article from the American Journal of Hematology covers the best new therapies for chronic myelomonocytic leukemia in 2022.

    .

  • July 13, 2022  

    Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022 Bookmark

    George Lundberg, MD

    Written for oncology healthcare professionals, this article from the ASCO Educational Book covers targeted therapies and immunotherapies that are now available to improve the prospects of people with acute myeloid leukemia.

    .

  • July 13, 2022  

    10 Years in CLL: Top Advances From 2012-2022 Bookmark

    George Lundberg, MD

    Published by Targeted Therapies in Oncology for healthcare professionals, this article outlines how novel targeted therapies have largely replaced chemotherapy and prolonged life greatly for people with chronic lymphocytic leukemia (CLL).

    .

  • July 13, 2022  

    ASCO 2022 Lymphoma In-Depth Bookmark

    George Lundberg, MD

    Presented by Cancer Therapy Advisor, this collection of stories covers new developments in lymphoma treatment that were presented at the 2022 annual meeting of the American Society of Clinical Oncology.

    .

  • July 1, 2022  

    Lymphoma: New Diagnosis and Current Treatment Strategies Bookmark

    George Lundberg, MD

    Read about personalized and targeted treatments for many types of lymphoma in this scientific review paper written for medical and research professionals and published in the Journal of Clinical Medicine.

    .

    .

  • July 1, 2022  

    Early Study Finds New Lymphoma Drug Effective Bookmark

    George Lundberg, MD

    According to this Newswise press release from Michigan Medicine – University of Michigan, the U.S. Food and Drug Administration (FDA) has approved the drug zanubrutinib to treat marginal zone lymphoma in some patients, based in part on results from a clinical trial led by researchers at University of Michigan Medical School that demonstrated an 80% response rate.

    .

  • June 14, 2022  

    How an Expert Would Manage His Own Advanced Prostate Cancer

    With: Marc B. Garnick, MD

    When facing a new cancer diagnosis, some people ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George asks Marc B. Garnick, MD, how he would handle his own advanced prostate cancer. Dr. Garnick is the Gorman Brothers Professor of Medicine at Harvard Medical School (HMS) and Beth Israel Deaconess Medical Center in Boston, MA. He is also… Read more »

  • June 13, 2022  

    ‘Unprecedented’ 100% of First 14 Untreated Patients With Rectal Cancer Respond to PD-1 Blocker Dostarlimab-gxly Bookmark

    George Lundberg, MD

    In a remarkable new study, covered in this article from The ASCO Post, 100% of 14 previously untreated patients with mismatch repair-deficient rectal cancer had complete responses—that is, no more signs of their cancer—after treatment with the checkpoint-inhibitor drug dostarlimab (brand name Jemperli) in a phase 2 clinical trial.

    .

  • June 13, 2022  

    Colon Cancer Treatment & Management Bookmark

    George Lundberg, MD

    Written for physicians and healthcare professionals, Medscape provides this trustworthy, encyclopedic resource for treating and managing metastatic colorectal cancer.

    .

  • June 13, 2022  

    Latest Evidence on Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer: A 2022 Update Bookmark

    George Lundberg, MD


    This scientific research paper from Critical Reviews in Oncology/Hematology discusses current options for treatments known as immune checkpoint inhibitors for people with advanced colorectal cancer.

    .